Brain Radiotherapy With Pyrotinib and Capecitabine in Patients With ERBB2-Positive Advanced Breast Cancer and Brain Metastases: A Nonrandomized Phase 2 Trial.

ABSTRACT:

Importance

The potential benefit of combining intracranial effective systemic therapy with radiotherapy for patients with breast cancer with brain metastases remains unclear.

Objective

To assess the activity and safety of combining radiotherapy with pyrotinib and capecitabine in patients with ERBB2-positive breast cancer and brain metastases.

Design, setting, and participants

This was a single-arm, single-center, phase 2 nonrandomized clinical trial with a safety run-in phase. Between January 2020 and August 2022, patients with ERBB2-positive breast cancer and brain metastases were enrolled. The data cutoff date was February 1, 2023.

Interventions

Patients received either fractionated stereotactic radiotherapy or whole-brain radiotherapy. Treatment with pyrotin

SUBMITTER: Yang Z 

PROVIDER: S-EPMC10767641 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature